Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05018650
Other study ID # CIP 0974
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date December 21, 2021
Est. completion date June 1, 2024

Study information

Verified date June 2023
Source Route 92 Medical, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The SUMMIT MAX study is a prospective, randomized, controlled, interventional clinical trial to evaluate the safety and effectiveness of the Route 92 Medical MonoPoint® Reperfusion System with the Hi Point 88 and HiPoint 70 Reperfusion Catheters for aspiration thrombectomy in acute ischemic stroke patients.


Description:

The purpose of the SUMMIT MAX study is to obtain the safety and effectiveness data necessary to demonstrate substantial equivalence of the Route 92 Medical Reperfusion System with a predicate aspiration device to support a 510(k) application to the U.S. Food and Drug Administration (FDA) under the classification product code, NRY.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 250
Est. completion date June 1, 2024
Est. primary completion date June 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. The consent process has been completed and documented according to applicable country regulations and as approved by the IRB / Ethics Committee 2. Age >=18 years 3. Patient presenting with clinical signs consistent with an acute ischemic stroke 4. Baseline National Institutes of Health Stroke Scale (NIHSS) score >= 6 5. Pre-stroke modified Rankin Score (mRS) <= 2 6. Baseline ASPECTS >= 6 7. Endovascular treatment initiated (defined as time of groin puncture) within 8 hours from time last known well 8. If indicated, thrombolytic therapy shall be initiated per clinical guidelines. If eligible for thrombolytic therapy, subjects should be treated as soon as possible and lytic use should not be delayed regardless of potential eligibility for mechanical neurothrombectomy. 9. The patient is indicated for aspiration neurothrombectomy with the Route 92 Medical Reperfusion System as determined by the Investigator 10. Angiographic confirmation of a large vessel occlusion of the M1 segment of the middle cerebral artery or distal internal carotid artery Exclusion Criteria: 1. Known pregnancy or breast feeding 2. In the Investigator's opinion, any known comorbidity (including COVID-19 positivity) that may complicate treatment or prevent improvement or follow-up 3. Known serious, advanced, or terminal illness with anticipated life expectancy < 12 months 4. Known history of severe allergy to contrast medium 5. Known to have suffered a stroke in the past 90 days 6. Known connective tissue disorder affecting the arteries (e.g. Marfan syndrome, Ehlers-Danlos syndrome) 7. Any known previous cerebral hemorrhagic event 8. Any known pre-existing coagulation deficiency 9. Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR >3.0 10. Known baseline platelet count <50,000/µL 11. Known baseline blood glucose of <50 mg/dL or >400 mg/dL 12. Known to be participating in another study involving an investigational device or drug 13. Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories. 14. Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) evidence of recent/ fresh cerebral hemorrhage (the presence of microbleeds is allowed) 15. Baseline CT or MRI showing intracranial tumor (except small meningioma <= 2cm) or significant mass effect with midline shift due to the tumor 16. Presumed septic thrombus, or suspicion of bacterial endocarditis 17. Inability to access the cerebral vasculature in the opinion of the neurointerventional team 18. Unlikely to be available for a 90-day follow-up (e.g. no fixed home address) 19. Evidence of arterial dissection in a vessel that must be traversed 20. Evidence of high-grade stenosis or occlusion (i.e., tandem occlusion) in a vessel that must be traversed 21. Known active or recent history of cocaine or methamphetamine abuse (within last 6 months) 22. Known history or presence of aneurysm or arteriovenous malformation (AVM) in the territory of the target lesion 23. For all patients, severe sustained hypertension with SBP >200 and/or DBP >120; for patients treated with a lytic, sustained hypertension despite treatment with SBP >185 and/or DBP >110 24. Treatment with heparin within 48 hours with a partial thromboplastic time more than two times the laboratory normal or treatment with any LMWH within 48 hours 25. Renal failure with serum creatinine >3.0 or Glomerular Filtration Rate (GFR) <30 26. Ongoing seizure due to stroke 27. Evidence of active systemic infection 28. Known cancer with metastases 29. Angiographic evidence of a dissection in the extracranial or intracranial cerebral arteries 30. Arterial stenosis requiring balloon angioplasty or stenting at the time of the procedure 31. Angiographic evidence of multiple cerebrovascular occlusions (e.g., bilateral anterior circulation, anterior/posterior circulation, tandem occlusions) 32. Angiographic evidence of known or suspected underlying intracranial vasculopathy or atherosclerotic lesions responsible for the target occlusion 33. Angiographic evidence or suspicion of aortic dissection 34. Angiographic evidence of an aneurysm or arteriovenous malformation (AVM) in the territory of the target lesion

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Route 92 Medical Reperfusion System
Mechanical thrombectomy for acute ischemic stroke patients with large vessel occlusions will be performed with direct aspiration consisting of navigating a large-bore catheter up to the face of the clot and initiating vacuum suction.

Locations

Country Name City State
New Zealand Auckland City Hospital Auckland
United States Boston Medical Center Boston Massachusetts
United States Tufts Boston Massachusetts
United States Cooper Health System Camden New Jersey
United States Mercy San Juan Medical Center Carmichael California
United States Advocate Aurora Health Chicago Illinois
United States Cleveland Clinic Cleveland Ohio
United States Ohio Health Columbus Ohio
United States University of Texas Southwestern Dallas Texas
United States Geisinger Clinic Danville Pennsylvania
United States Wright State University Dayton Ohio
United States Valley Baptist Harlingen Texas
United States Baptist Jacksonville Jacksonville Florida
United States Saint Luke's Kansas City Missouri
United States University of Kansas Kansas City Kansas
United States Fort Sanders Medical Center Knoxville Tennessee
United States Baptist Health Lexington Lexington Kentucky
United States Banner Health Mesa Arizona
United States Baptist Hospital of Miami Miami Florida
United States West Virginia University Morgantown West Virginia
United States Christiana Care Newark Delaware
United States Thomas Jefferson University Philadelphia Pennsylvania
United States Rutgers Piscataway New Jersey
United States UPMC Pittsburgh Pennsylvania
United States Medical City Plano Plano Texas
United States OHSU Portland Oregon
United States University of Utah Salt Lake City Utah
United States Stony Brook University Hospital Stony Brook New York
United States Mercy Health St. Vincent Toledo Ohio
United States University of Massachusetts Worcester Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Route 92 Medical, Inc.

Countries where clinical trial is conducted

United States,  New Zealand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of subjects with successful arterial revascularization defined as a modified Thrombolysis in Cerebrovascular Infarction (mTICI) score of 2b or greater mTICI of 2b or greater indicates successful reperfusion following blood clot removal During procedure
Primary Incidence of all symptomatic intracerebral hemorrhage (sICH) Evaluation of sICH per von Kummer et al within 24 hours post-procedure
See also
  Status Clinical Trial Phase
Recruiting NCT06113848 - Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy Phase 3
Completed NCT04069546 - The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency N/A
Active, not recruiting NCT05700097 - Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy Phase 2
Recruiting NCT06058130 - Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis N/A
Recruiting NCT04415164 - Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke Phase 4
Recruiting NCT05363397 - Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke Phase 2
Completed NCT05429658 - Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System N/A
Recruiting NCT05390580 - Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct N/A
Enrolling by invitation NCT05515393 - A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke Phase 2
Active, not recruiting NCT05070260 - ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo Phase 2/Phase 3
Terminated NCT05547412 - Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
Completed NCT03366818 - New Stent Retriever, VERSI System for AIS N/A
Not yet recruiting NCT06437431 - Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy Phase 2/Phase 3
Not yet recruiting NCT06040476 - Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS) Phase 2
Not yet recruiting NCT05293080 - Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE Phase 3
Completed NCT02223273 - Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke) N/A
Completed NCT02586233 - Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke Phase 1/Phase 2
Not yet recruiting NCT01594190 - Physical Activity Immediately After Acute Cerebral Ischemia N/A
Terminated NCT01694381 - Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor Early Phase 1
Completed NCT01120301 - Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3) Phase 3